Business Context and Reporting Period
This Form 8-K filing by Acrivon Therapeutics, Inc. (ACRV) covers the reporting period ending February 25, 2026. The report details the termination of a material definitive agreement with Akoya Biosciences, a subsidiary of Quanterix Corporation, following the completion of Acrivon's own CLIA-certified laboratory in Watertown, Massachusetts.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The transaction described involves no financial payments from or to either party.
Material Changes
- Termination of Agreement: On February 25, 2026, Acrivon terminated the OncoSignature Companion Diagnostic Agreement dated June 17, 2022, with Akoya Biosciences.
- Operational Shift: Acrivon has transitioned ACR-368 OncoSignature testing from Akoya to its newly operational, in-house CLIA-certified laboratory.
- Intellectual Property: Effective immediately, Acrivon secured full development and commercialization rights to its proprietary ACR-368 OncoSignature test.
- Transition Plan: Quanterix will continue to meet clinical testing requirements during the transfer period to support the ongoing registrational-intent Phase 2b study.
Outlook, Management Commentary, and Risks
Management states that bringing CLIA operations in-house provides enhanced capabilities and efficiencies for developing targeted therapeutic agents. Key benefits cited include full control over predictive biomarker identification, companion diagnostic development, indication finding, and the streamlining of co-regulatory approvals and co-commercialization. The filing does not explicitly list new risks or contingencies arising from this specific termination, noting only the ongoing support from Quanterix during the transition.
Investor Verification Checklist
- Confirm the operational readiness and certification status of Acrivon's new internal CLIA laboratory.
- Verify the timeline for the complete transfer of ACR-368 OncoSignature testing from Quanterix to Acrivon.
- Assess the impact of this transition on the timeline and data integrity of the ongoing Phase 2b study.
- Review future capital expenditure requirements for maintaining the in-house laboratory versus previous outsourcing costs.